Skip to main content

Table 3 Clinicopathological characteristics in association with ROS1 gene rearrangement

From: The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt

   ROS1 FISH p-value
N -ve +ve  
Age
 < 55 32 26 (81.25) 6 (18.75) 0.74a
 ≥ 55 38 33 (86.80) 5 (13.20)
Gender
 Female 19 17 (89.50) 2 (10.50) 0.71a
 Male 51 42 (83.35) 9 (16.65)
Smoking status
 Never-smoker 27 23 (85.20) 4 (14.80) 1.00a
 Current/ex-smoker 43 36 (83.70) 7 (16.30)
Grade
 1–2 51 43 (84.30) 8 (15.70) 1.00a
 3 19 16 (84.20) 3 (15.80)
Stage
 I 12 8 (66.67) 4 (33.33) 0.24b
 II 15 14 (93.30) 1 (6.70)
 III 12 11 (91.67) 1 (8.33)
 IV 31 26 (83.80) 5 (16.20)
Tumor size (cm)
 < 4 25 21 (84.00) 4 (16.00) 1.00a
 ≥ 4 45 38 (84.40) 7 (15.60)
Laterality
 Left 36 28 (77.80) 8 (22.20) 0.19a
 Right 34 31 (91.20) 3 (8.80)
LN metastasis
 No 34 29 (85.30) 5 (14.70) 1.00a
 Yes 36 30 (83.33) 6 (16.67)
EGFR mutation
 Wild type 40 35 (87.50) 5 (12.50) 0.47b
 Mutant 21 16 (76.20) 5 (23.80)
 Unknown 9 8 (88.90) 1 (11.10)
  1. LN lymph node, EGFR epidermal growth factor receptor, ROS1 c-ros oncogene1
  2. aFisher exact test was used
  3. bChi-square test was used